All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
A Federal Circuit decision that tribal sovereign immunity cannot be asserted in inter partes reviews (IPRs) could be the slippery slope that eventually makes biopharma and med-tech patents held by state universities fair game for IPR challenges.